Status
Conditions
Treatments
About
This study is being proposed to evaluate the use of moderate hypofractionated proton therapy in low and intermediate risk prostate cancer patients. Quality of life outcomes as well as gastrointestinal and genitourinary early and late toxicities will be analyzed and compared to conventional proton therapy regimens. It is thought that this regimen will produce comparable findings and would result in substantial health care cost savings, as well as, be more convenient for patients.
Full description
Patients will receive: 62 Gy (RBE) in 20 fractions of 3.1 Gy (RBE) over 4 weeks
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Pathological (histologically) proven diagnosis of prostatic adenocarcinoma within 365 days (1 year) prior to study registration.
Exclusion criteria
• Prior radiotherapy to the pelvic area.
Primary purpose
Allocation
Interventional model
Masking
235 participants in 2 patient groups
Loading...
Central trial contact
Natalie E Freeman, PhD; Brenda J Whitehead, CCRP
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal